Non-COVID mRNA Vaccines & Therapeutics Market
完整報告名稱與涵蓋範圍
Non-COVID mRNA Vaccines & Therapeutics Market Size, Share & Trends Analysis Report, By Product Category (Infectious Disease Vaccines (RSV, Influenza, CMV and Others), Personalized and Shared-Antigen Cancer Vaccines, Protein Replacement and Rare Disease Therapeutics, Immunotherapies and Other Applications), By Development Stage (Approved and Commercial, Phase 3, Phase 1 and Phase 2), By Route of Administration (Intramuscular, Intravenous and Other Routes), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The non-COVID mRNA vaccines and therapeutics market covers messenger RNA products for indications other than COVID-19, including approved and pipeline vaccines against RSV, influenza, cytomegalovirus and other pathogens, personalised and shared-antigen cancer vaccines, protein replacement and rare disease therapeutics and mRNA-encoded immunotherapies. COVID-19 vaccines are excluded, as are the raw material and manufacturing service markets covered in other InsightAce studies.
The category is the commercial test of whether mRNA becomes a broad platform: the first non-COVID approval for RSV in older adults, late-stage combination respiratory vaccines and pivotal trials of individualised neoantigen therapy in melanoma and other cancers define the near-term revenue path. Beyond vaccines, protein replacement programs for metabolic disease and in vivo editing payloads extend the technology, while next-generation constructs improve durability and reduce reactogenicity. Commercial performance depends on demonstrating advantages over established protein and conjugate vaccines, on regulatory positions regarding platform data, and on manufacturing economics for personalised products.
The United States, Europe and Japan account for most revenue, with China and India developing domestic mRNA vaccines and manufacturing. Competition involves mRNA pioneers, vaccine incumbents licensing or building mRNA capabilities and Asian biotechnology companies.
The InsightAce study provides US$ revenue forecasts for every product category, development stage, route of administration and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-COVID mRNA Vaccines & Therapeutics Market Snapshot
Chapter 4. Global Non-COVID mRNA Vaccines & Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Category Estimates & Trend Analysis
5.1. Product Category & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Category:
5.2.1. Infectious Disease Vaccines (RSV, Influenza, CMV and Others)
5.2.2. Personalized and Shared-Antigen Cancer Vaccines
5.2.3. Protein Replacement and Rare Disease Therapeutics
5.2.4. Immunotherapies and Other Applications
Chapter 6. Market Segmentation 2: By Development Stage Estimates & Trend Analysis
6.1. Development Stage & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
6.2.1. Approved and Commercial
6.2.2. Phase 3
6.2.3. Phase 1 and Phase 2
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Intramuscular
7.2.2. Intravenous and Other Routes
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Vaccination Centers
8.2.2. Retail Pharmacies and Clinics
8.2.3. Government Immunization Programs
Chapter 9. Non-COVID mRNA Vaccines & Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Moderna, Inc.
11.2. Pfizer Inc.
11.3. BioNTech SE
11.4. Arcturus Therapeutics Holdings Inc.
11.5. CureVac N.V. (BioNTech)
11.6. CSL Seqirus
11.7. Sanofi
11.8. GSK plc
11.9. Merck & Co., Inc.
11.10. Novavax, Inc. (mRNA Partnerships)
11.11. Daiichi Sankyo Company, Limited
11.12. Abogen Biosciences Co., Ltd.
11.13. Walvax Biotechnology Co., Ltd.
11.14. Gennova Biopharmaceuticals Limited
11.15. Strand Therapeutics, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Non-COVID mRNA Vaccines & Therapeutics Market Revenue Forecast by Product Category, 2026-2035 (US$ Mn)
Figure 1. Global Non-COVID mRNA Vaccines & Therapeutics Market Segmentation Overview
Table 2. Global Non-COVID mRNA Vaccines & Therapeutics Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 2. Global Non-COVID mRNA Vaccines & Therapeutics Market Share by Product Category, 2026 & 2035
Table 3. Global Non-COVID mRNA Vaccines & Therapeutics Market Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Non-COVID mRNA Pipeline by Indication, Phase and Sponsor, 2026
Table 4. Global Non-COVID mRNA Vaccines & Therapeutics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Non-COVID mRNA Vaccines & Therapeutics Market Share by Development Stage, 2026 & 2035
Table 5. North America Non-COVID mRNA Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Revenue Build from Respiratory Vaccines to Personalised Cancer Therapy, 2026-2035
Table 6. Europe Non-COVID mRNA Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Non-COVID mRNA Vaccines & Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Non-COVID mRNA Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of mRNA Versus Established Vaccine Platforms by Pathogen
Table 8. Latin America Non-COVID mRNA Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Non-COVID mRNA Vaccines & Therapeutics Market Participants
Table 9. Middle East & Africa Non-COVID mRNA Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們